Can unicorns float? Is a hot dog a sandwich? And how are drug companies like gas stations?
We discuss all that and more on the latest episode of “The Readout LOUD,” STAT’s biotech podcast. First, we dive into Moderna Therapeutics’ ambition to pull off the biggest IPO in biotech history at a time when the sector is having a hard time convincing investors of its promise. Then, STAT’s Casey Ross joins us to talk about his investigation into lockstep price increases for a pair of blockbuster drugs and the effects they have on patients. Finally, biopharma veteran and Yumanity Therapeutics CEO Dr. Tony Coles sits down to talk about his career, the future of neuroscience, and burner Twitter accounts.
For more on what we cover, here’s the latest on Moderna; here’s the story on price increases to Humira and Enbrel; and here’s more on Coles’ political action committee.
We’re taking Thanksgiving off, but we’ll back Nov. 29 — and every Thursday evening thereafter — so be sure to sign up on iTunes, Stitcher, Google Play, or wherever you get your podcasts.
And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].
Interested in sponsoring a future episode of “The Readout LOUD”? Email us at [email protected].